反-1,2-环丙烷二羧酸二甲酯 | 826-35-7

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 反-1,2-环丙烷二羧酸二甲酯
• 中文别名: 反式-1,2-环丙二羧酸二甲酯；反式-1,2-环丙烷二羧酸二甲酯
• 英文名称: dimethyl trans-1,2-cyclopropanedicarboxylate
• 英文别名: dimethyl (±)-trans-cyclopropane-1,2-dicarboxylate；dimethyl trans-cyclopropane-1,2-dicarboxylate；trans-dimethyl cyclopropane-1,2-dicarboxylate；1,2-dimethyl cyclopropane-1,2-dicarboxylate；trans-dimethyl cyclopropane dicarboxylate；dimethyl trans-cyclopropanedicarboxylate；dimethyl (1R,2R)-cyclopropane-1,2-dicarboxylate
• CAS: 826-35-7
• 化学式: C₇H₁₀O₄
• 分子量: 158.154
• InChiKey: JBVOSZYUSFDYIN-RFZPGFLSSA-N

物化性质

• 熔点：
  173 °C
• 沸点：
  101 °C (18 mmHg)
• 密度：
  1.12
• 溶解度：
  可溶于氯仿、二氯甲烷、甲醇（微溶）
• 保留指数：
  1090
• 稳定性/保质期：
  在常温常压下稳定，应避免与不相容材料接触。与强氧化剂反应。

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R22
• 海关编码：
  2917209090
• 危险性防范说明：
  P264,P270,P301+P312+P330,P501
• 危险性描述：
  H302
• 储存条件：
  密封储存，应存放在阴凉、干燥的仓库中。

SDS

Name:	2 2 6 6-Tetramethyl-4-Piperidone Monohydrate 98% (GC) Material Safety Data Sheet
Synonym:	Triacetoneamine Hydrate; 4-Oxo-2,2,6,6-Tetramethylpiperidine
CAS:	826-35-7

Section 1 - Chemical Product MSDS Name:2 2 6 6-Tetramethyl-4-Piperidone Monohydrate 98% (GC) Material Safety Data Sheet
Synonym:Triacetoneamine Hydrate; 4-Oxo-2,2,6,6-Tetramethylpiperidine

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
826-35-7	2,2,6,6-Tetramethyl-4-Piperidone, Mono	99+%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
In case of fire, use water, dry chemical, chemical foam, or alcohol-resistant foam. Use agent most appropriate to extinguish fire.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Keep refrigerated. (Store below 4C/39F.)

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Exposure Limits CAS# 826-35-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: white to light tan
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 57.50 - 60.50 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H17NO.H2O
Molecular Weight: 173.26

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 826-35-7 unlisted.
LD50/LC50:
Not available.
Rat: LD50 - ROUTE: Intraperitoneal; DOSE: 385 mg/kg ROUTE: Oral; DOSE: 1539 mg/kg DOSE: 500 mg/kg Carcinogenicity:
2,2,6,6-Tetramethyl-4-Piperidone, Monohydrate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 826-35-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 826-35-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 826-35-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  反-1,2-环丙烷二羧酸二甲酯 在 sodium hydroxide 、 水 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以99%的产率得到反式 环丙烷-1,2-二羧酸
  参考文献：
  名称：

  一些头对头连接的DNA小沟结合剂的合成

  摘要：

  已经制备了一系列首尾相连的杂环氨基酸二聚体，用于研究与DNA小沟结合的亲和力和选择性。合成目标的选择由基于计算机的设计主导。已经包括几种新颖的二羧酸连接基，包括吲哚，菲，芴酮和双苯并噻吩。通过印迹分析与DNA的结合表明对衍生自2,7-二氢菲二羧酸的化合物具有很高的亲和力，并且对包含至少4个AT对的AT富集区域具有主要选择性，但具有跨越两个CG碱基对的能力。

  DOI：

  10.1016/s0040-4020(00)00432-4
• 作为产物：
  描述：

  1,5-dimethoxy-1,5-bis[(trimethylsilyl)oxy]penta-1,4-diene 在 四氯化钛 作用下， 以 二氯甲烷 为溶剂， 以20%的产率得到反-1,2-环丙烷二羧酸二甲酯
  参考文献：
  名称：

  1,5-双（三甲基甲硅烷氧基）-1，5-二甲氧基-1，4-戊二烯：合成环丙烷和环丁烷的前体

  摘要：

  通过将戊二酸二甲酯（8）的二价硅烷基化，可以高收率制备1，5-双（三甲基甲硅烷氧基）-1、5-二甲氧基-1、4-戊二烯（7）。在用四氯化钛处理时，7环化立体选择性地二甲基反式-环丙烷-1，2-二羧酸盐10。7与乙酸酐和四氯化钛反应生成取代的环丁烷22b–d。

  DOI：

  10.1016/s0040-4020(01)88582-3

文献信息

• Reductive cleavage of succinic esters. A method for the introduction of acetic acid fragments
  作者：Paul G. Gassman、Xavier Creary

  DOI：10.1039/c39720001214

  日期：——

  Diels–Alder addition of maleic or fumaric esters to 1,3-dienes, followed by catalytic reduction and treatment with sodium in liquid ammonia at –78°, which promotes a solvent dependent reductive cleavage of the carbon–carbon σ bond of the succinic ester fragment, provides a general method for the preparation of derivatives of suberic acid.

  Diels–将马来酸酯或富马酸酯加到1,3-二烯中，然后催化还原并在–78°下用液态氨中的钠进行处理，从而促进了琥珀酸酯的碳-碳σ键的溶剂依赖性还原裂解片段提供了一种制备辛二酸衍生物的通用方法。
• Facile synthesis of libraries of functionalized cyclopropanes and oxiranes using ionic liquids – A new approach to the classical Corey-Chaykovsky reaction
  作者：Shruti S. Malunavar、Suraj M. Sutar、Pavankumar Prabhala、Hemantkumar M. Savanur、Rajesh G. Kalkhambkar、Gopalakrishnan Aridoss、Kenneth K. Laali

  DOI：10.1016/j.tetlet.2021.153339

  日期：2021.9

  [PAIM][NTf]/BMIM-ILs as a base/solvent in the Corey-Chaykovsky reaction is demonstrated by the facile synthesis of libraries of functionalized cyclopropanes from enones and oxiranes from aldehydes and ketones, at room temperature in respectable isolated yields. To demonstrate their application, the synthesized epoxides were employed as substrates for the synthesis of a library of 2,3-disubstituted quinolines, using

  [PAIM][NTf]/BMIM-IL 在 Corey-Chaykovsky 反应中作为碱/溶剂的潜力通过在室温下以相当高的分离度从烯酮和环氧乙烷轻松合成官能化环丙烷库来证明。产量。为了证明其应用，合成的环氧化物被用作合成 2,3-二取代喹啉库的底物，使用 [BMIM(SOH)][OTf]/[BMIM][PF] 作为催化剂/溶剂。还探讨了离子液体溶剂回收/再利用的潜力。
• SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES
  申请人：Pouzet Pascale

  公开号：US20110021501A1

  公开（公告）日：2011-01-27

  The invention relates to new piperidino-dihydrothienopyrimidines of formula 1, as well as pharmacologically acceptable salts thereof, wherein X is SO or SO 2 , but preferably SO, and wherein R 1 , R 2 , R 3 and R 4 may have the meanings given in claim 1 , as well as pharmaceutical compositions which contain these compounds. These new piperidino-dihydrothienopyrimidines are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers.

  本发明涉及通式1的新哌啶二氢噻吩并嘧啶类化合物及其药理上可接受的盐，其中X为SO或SO2，优选SO，并且其中R1、R2、R3和R4可具有权利要求1中所述的含义，以及含有这些化合物的药物组合物。这些新哌啶二氢噻吩并嘧啶类化合物适用于治疗呼吸系统或胃肠道疾病、关节、皮肤或眼睛的炎症性疾病、周围或中枢神经系统疾病或癌症。
• CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20170253554A1

  公开（公告）日：2017-09-07

  The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein coupled receptor modulators which may be used as medicaments

  本发明提供了Formula（I）的化合物：或其立体异构体，或其药用可接受盐，其中所有变量如本文所定义。这些化合物是GPR120 G蛋白偶联受体调节剂，可以用作药物。
• Highly Enantioselective Oxidation of <i>cis</i>-Cyclopropylmethanols to Corresponding Aldehydes Catalyzed by Chloroperoxidase
  作者：Shanghui Hu、Jonathan S. Dordick

  DOI：10.1021/jo016161i

  日期：2002.1.1

  catalyzes the enantioselective oxidation of cyclopropylmethanols. This finding enables a novel route to the synthesis of optically active cyclopropane derivatives, which occur widely in natural products and compounds of pharmaceutical interest. In addition, chiral cyclopropane molecules may be useful model substrates to investigate reaction mechanisms of CPO and the related cytochromes P450.

  氯过氧化物酶（CPO）使用叔丁基氢过氧化物作为末端氧化剂，催化环丙基甲醇（例如2-甲基环丙基甲醇）的对映选择性氧化为环丙基醛。在所有情况下，尽管CPO对两种异构体都具有相似的催化活性，但顺式环丙烷的CPO氧化显示出比反式异构体高得多的对映选择性。这是血红素酶催化环丙基甲醇对映选择性氧化的第一个例子。该发现为光学活性环丙烷衍生物的合成提供了一条新途径，该化合物广泛存在于天然产物和具有药物意义的化合物中。此外，手性环丙烷分子可能是研究CPO与相关细胞色素P450反应机理的有用模型底物。